Table 2.

Local failure (LF) location, type of LF and V_95%, D_95% normalized by the prescription doses

Patient	LF Location	Type of LF	D95% (%)		V95% (%)
			PTVHigh	PTVLow	PTVHigh	PTVLow
1	Left level II lymph node	Out‐of‐field	94.8	81.3	93.9	83.9
2	Inferior left nasopharynx	In‐field	100.0	99.5	100.0	100.0
3	Left lower neck posterior to the sternocleidomastoid muscle	Marginal	100.1	100.0	100.0	100.0
4	Left IIA and IV lymph nodes	In‐field, In‐field	101.8	101.6	99.0	99.0
5	Left I and II lymph nodes	In‐field	100.0	100.0	100.0	99.5
6	Floor of mouth and left neck base	Marginal, Marginal	100.0	101.9	100.0	99.9
7	Floor of mouth and right tongue	In‐field, In‐field	100.0	100.9	100.0	99.9
8	Posterior nasopharyngeal abutting the skull base and clivus	In‐field	97.2	100.6	95.5	98.9
9	Left II and IV lymph nodes	In‐field	98.5	94.8	100.0	99.4
10	Left buccal space	In‐field	100.5	100.9	100.0	97.9

D_95%, the dose covering 95% of the PTV; PTV, planning target volume; V_95%, the subvolume of the PTV receiving 95% of the prescription dose.